KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Enterprise Value (2018 - 2025)

Esperion Therapeutics' Enterprise Value history spans 8 years, with the latest figure at -$167.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 15.95% year-over-year to -$167.9 million; the TTM value through Dec 2025 reached -$167.9 million, down 15.95%, while the annual FY2025 figure was -$167.9 million, 15.95% down from the prior year.
  • Enterprise Value reached -$167.9 million in Q4 2025 per ESPR's latest filing, down from -$92.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$82.2 million in Q4 2023 to a low of -$259.3 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$161.2 million, with a median of -$164.6 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: crashed 82.63% in 2022, then skyrocketed 54.54% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$259.3 million in 2021, then skyrocketed by 35.66% to -$166.9 million in 2022, then soared by 50.71% to -$82.2 million in 2023, then tumbled by 76.01% to -$144.8 million in 2024, then dropped by 15.95% to -$167.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Enterprise Value are -$167.9 million (Q4 2025), -$92.4 million (Q3 2025), and -$86.1 million (Q2 2025).